Conv. Plasma
Nigella Sativa
Peg.. Lambda

All convalescent plasma..
Meta analysis
Home COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 45% Improvement Relative Risk Ventilation 69% Progression 19% Oxygen time -57% Hospitalization time -62% Conv. Plasma  Holm et al.  LATE TREATMENT  RCT Is late treatment with convalescent plasma beneficial for COVID-19? RCT 31 patients in Sweden (June 2020 - January 2021) Lower ventilation (p=0.45) and higher oxygen therapy (p=0.43), not sig. Holm et al., BMC Research Notes, December 2021 Favors conv. plasma Favors control

Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden

Holm et al., BMC Research Notes, doi:10.1186/s13104-021-05847-7, NCT04600440
Dec 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 31 hospitalized patients requiring supplemental oxygen in Sweden, showing no significant difference in outcomes with convalescent plasma.
risk of death, 45.1% lower, RR 0.55, p = 0.64, treatment 2 of 17 (11.8%), control 3 of 14 (21.4%), NNT 10.
risk of mechanical ventilation, 68.9% lower, RR 0.31, p = 0.45, treatment 0 of 17 (0.0%), control 1 of 14 (7.1%), NNT 14, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of progression, 18.8% lower, RR 0.81, p = 1.00, treatment 4 of 16 (25.0%), control 4 of 13 (30.8%), NNT 17, progression to HFNC.
oxygen time, 57.1% higher, relative time 1.57, p = 0.43, treatment 17, control 14.
hospitalization time, 62.5% higher, relative time 1.62, p = 0.21, treatment 17, control 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Holm et al., 4 Dec 2021, Randomized Controlled Trial, Sweden, peer-reviewed, 14 authors, study period June 2020 - January 2021, average treatment delay 7.0 days, trial NCT04600440 (history).
Contact: (corresponding author).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden
Karin Holm, Maria N Lundgren, Jens Kjeldsen-Kragh, Oskar Ljungquist, Blenda Böttiger, Christian Wikén, Jonas Öberg, Nils Fernström, Ebba Rosendal, Anna K Överby, Julia Wigren Byström, Mattias Forsell, Mona Landin-Olsson, Magnus Rasmussen
BMC Research Notes, doi:10.1186/s13104-021-05847-7
Objective: Convalescent plasma has been tried as therapy for various viral infections. Early observational studies of convalescent plasma treatment for hospitalized COVID-19 patients were promising, but randomized controlled studies were lacking at the time. The objective of this study was to investigate if convalescent plasma is beneficial to hospitalized patients with COVID-19. Results: Hospitalized patients with confirmed COVID-19 and an oxygen saturation below 94% were randomized 1:1 to receive convalescent plasma in addition to standard of care or standard of care only. The primary outcome was number of days of oxygen treatment to keep saturation above 93% within 28 days from inclusion. The study was prematurely terminated when thirty-one of 100 intended patients had been included. The median time of oxygen treatment among survivors was 11 days (IQR 6-15) for the convalescent plasma group and 7 days (IQR 5-9) for the standard of care group (p = 0.4, median difference -4). Two patients in the convalescent plasma group and three patients in the standard of care group died (p = 0.64, OR 0.49, 95% CI 0.08-2.79). Thus no significant differences were observed between the groups.
Abbreviations Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1186/ s13104-021-05847-7. Additional file 1. SARS-CoV2 antibody detection and microneutralization assay. Authors' contributions KH: study design, inclusion of patients and donors, data collection and analysis, manuscript writing. MNL: study design, transfusion medicine expertise, donor screening and responsible for plasma collection and plasma analysis, data analysis and manuscript writing. JKK: study design, transfusion medicine expertise, data analysis and critical revision of the manuscript. OL, CW, JÖ: inclusion of patients, data collection and analysis, critical revision of the manuscript. NF: study design, inclusion of patients and donors, data collection. BB: study design, responsible for virology sampling and data analysis, critical revision of the manuscript. ER, AKÖ, JWB, MF: responsible for measuring Declarations Ethics approval and consent to participate The Swedish Ethical Review Authority approved the study (Reference Number #2020-01744, 2020-03595). Written informed consent was required from donors and patients on inclusion. Consent to publish Not applicable. Competing interests The authors declare no competing interests. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Agarwal, Mukherjee, Kumar, Chatterjee, Bhatnagar et al., Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ (Clin Res ed), doi:10.1136/bmj.m3939
Arabi, Hajeer, Luke, Raviprakash, Balkhy et al., Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia, Emerg Infect Dis, doi:10.3201/eid2209.151164
Betrains, Godinas, Woei, Rosseels, Van Herck et al., Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies, Br J Haematol, doi:10.1111/bjh.17266
Casadevall, Pirofski, The convalescent sera option for containing COVID-19, J Clin Invest, doi:10.1172/JCI138003
Cheng, Wong, Soo, Wong, Lee et al., Use of convalescent plasma therapy in SARS patients in Hong Kong, Eur J Clin Microbiol Infect Dis, doi:10.1007/s10096-004-1271-9
Duan, Liu, Li, Zhang, Yu et al., Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc Natl Acad Sci, doi:10.1073/pnas.2004168117
Hegerova, Gooley, Sweerus, Maree, Bailey et al., Use of convalescent plasma in hospitalized patients with COVID-19: case series, Blood, doi:10.1182/blood.2020006964
Horby, Estcourt, Peto, Emberson, Staplin et al., Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, doi:10.1101/2021.03.09.21252736
Hueso, Pouderoux, Péré, Beaumont, Raillon et al., Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19, Blood, doi:10.1182/blood.2020008423
Hung, To, Lee, Lee, Chan et al., Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection, Clin Infect Dis, doi:10.1093/cid/ciq106
Joyner, Wright, Fairweather, Senefeld, Bruno et al., Early safety indicators of COVID-19 convalescent plasma in 5000 patients, J Clin Investig, doi:10.1172/JCI140200
Libster, Marc, Wappner, Coviello, Bianchi et al., Early high-titer plasma therapy to prevent severe Covid-19 in older adults, N Engl J Med, doi:10.1056/NEJMoa2033700
Mair-Jenkins, Saavedra-Campos, Baillie, Cleary, Khaw et al., The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis, J Infect Dis, doi:10.1093/infdis/jiu396
Rodionov, Biener, Spieth, Achleitner, Hölig et al., Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19, Lancet Microbe, doi:10.1016/S2666-5247(21)00030-6
Rojas, Rodríguez, Monsalve, Acosta-Ampudia, Camacho et al., Convalescent plasma in Covid-19: possible mechanisms of action, Autoimmun Rev, doi:10.1016/j.autrev.2020.102554
Sahr, Ansumana, Massaquoi, Idriss, Sesay et al., Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone, J Infect, doi:10.1016/j.jinf.2016.11.009
Senefeld, Klassen, Ford, Wiggins, Bostrom et al., Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency, medRxiv, doi:10.1101/2020.11.08.20224790
Simonovich, Pratx, Scibona, Beruto, Vallone et al., A randomized trial of convalescent plasma in Covid-19 severe pneumonia, N Engl J Med, doi:10.1056/NEJMoa2031304
Zhou, Zhong, Guan, Treatment with convalescent plasma for influenza A (H5N1) Infection, N Engl J Med, doi:10.1056/NEJMc070359
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop